Related Experiment Videos
Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. off
1Preventive Cardiology Program, Department of Medicine, University of Wisconsin Medical School, Madison 53792, USA. jhs@medicine.wisc.edu
Insights
Hyperhomocysteinemia is a risk factor for vascular disease. Screening and treatment with folic acid supplements are recommended for high-risk patients to prevent cardiovascular events.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Nutritional Science
Background:
- Hyperhomocysteinemia, elevated homocysteine levels, is an emerging risk factor for atherosclerotic vascular disease.
- Understanding homocysteine metabolism and its pathological role is crucial for cardiovascular health.
- Epidemiological studies link high homocysteine levels to increased vascular disease risk.
Purpose of the Study:
- To review homocysteine metabolism, causes, pathophysiology, and epidemiological links to vascular disease.
- To provide evidence-based recommendations for screening and managing hyperhomocysteinemia.
- To guide the primary and secondary prevention of vascular disease in affected patients.
Main Methods:
- Comprehensive review of existing literature on homocysteine metabolism and vascular disease.
- Analysis of epidemiological data associating homocysteine levels with cardiovascular risk.
- Evaluation of treatment strategies, focusing on folic acid and multivitamin supplementation.
Main Results:
- Hyperhomocysteinemia is a significant risk factor for atherosclerotic vascular disease.
- Screening is advised for patients at high risk.
- Treatment thresholds are suggested for primary (≥14 µmol/L) and secondary (≥11 µmol/L) prevention.
Conclusions:
- Folic acid (400-1000 µg) and multivitamin supplements are recommended for treatment.
- Higher doses of folic acid and cyanocobalamin may be needed for some patients.
- Conservative management offers a safe, effective, evidence-based approach pending further clinical trials.
Abstract:
Hyperhomocysteinemia has recently been identified as an important risk factor for atherosclerotic vascular disease. This article reviews homocysteine metabolism, causes of hyperhomocysteinemia, the pathophysiological findings of this disorder, and epidemiological studies of homocysteine and vascular disease. Screening for hyperhomocysteinemia should be considered for patients at high risk for vascular disease or abnormalities of homocysteine metabolism. For primary prevention of vascular disease, treatment of patients with homocysteine levels of 14 micromol/L or higher should be considered. For secondary prevention, treatment of patients with homocysteine levels of 11 micromol/L or higher should be considered. Treatment is most conveniently administered as a folic acid supplement (400-1000 microg) and a high-potency multivitamin that contains at least 400 microg of folate. Higher doses of folic acid and cyanocobalamin supplements may be required in some patients. Until prospective clinical trial data become available, these conservative recommendations provide a safe, effective, and evidence-based approach to the diagnosis, evaluation, and management of patients with hyperhomocysteinemia.